Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PPB-R-205
- Development stage
- Unknown
- Lead developer
- Pharma Power Biotec
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
PPB-R-205 is a liquid gel/sol-gel drug delivery platform developed by Pharma Power Biotec. It is designed to act as a localized drug delivery matrix that undergoes a phase transition to retain and release therapeutic agents at a target site. The platform is specifically used as the delivery system for Radion-pdt, a photodynamic therapy (PDT) agent being developed for cancer indications including oral, cervical, and skin cancers. The technology provides extended-release capabilities to maintain therapeutic concentrations of the active agent at the tumor site.
- Other names
- liquid gel platformsol-gel delivery systemliquid gel/sol-gel platform
Beyond the preview
Go deeper on PPB-R-205.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PPB-R-205.